Hood River Capital Management LLC Acquires 10,622 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Hood River Capital Management LLC increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 2.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 512,726 shares of the company's stock after purchasing an additional 10,622 shares during the quarter. Krystal Biotech makes up approximately 1.2% of Hood River Capital Management LLC's portfolio, making the stock its 28th biggest holding. Hood River Capital Management LLC owned 1.78% of Krystal Biotech worth $80,324,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in KRYS. US Bancorp DE raised its holdings in shares of Krystal Biotech by 8.7% in the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after acquiring an additional 82 shares in the last quarter. Summit Investment Advisors Inc. increased its position in shares of Krystal Biotech by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company's stock worth $407,000 after purchasing an additional 82 shares during the last quarter. Crossmark Global Holdings Inc. raised its stake in Krystal Biotech by 5.5% in the fourth quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company's stock valued at $362,000 after purchasing an additional 121 shares in the last quarter. Envestnet Asset Management Inc. lifted its position in Krystal Biotech by 1.1% during the fourth quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company's stock valued at $1,822,000 after purchasing an additional 121 shares during the last quarter. Finally, Perigon Wealth Management LLC grew its stake in Krystal Biotech by 1.5% in the 4th quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company's stock worth $1,200,000 after buying an additional 123 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares in the company, valued at $260,233,178.69. This represents a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 13.70% of the company's stock.

Analyst Upgrades and Downgrades

KRYS has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. Chardan Capital upped their price objective on Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. HC Wainwright upped their target price on Krystal Biotech from $221.00 to $240.00 and gave the stock a "buy" rating in a research note on Monday. Citigroup lifted their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research note on Thursday, February 20th. Finally, Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 target price on the stock. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $222.71.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS traded down $0.71 during trading on Monday, reaching $167.35. 57,057 shares of the stock traded hands, compared to its average volume of 295,193. The stock has a market cap of $4.84 billion, a P/E ratio of 55.97 and a beta of 0.75. The stock has a 50-day moving average of $176.37 and a two-hundred day moving average of $171.56. Krystal Biotech, Inc. has a 52-week low of $141.72 and a 52-week high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. The business had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company's quarterly revenue was up 116.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.30 EPS. Sell-side analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).